Program

Vectibix slavi 20 godina: Dva desetljeća posvećenosti onkološkim bolesnicima
Vectibix Celebrates 20 Years: Two Decades of Commitment to Cancer Patients

Moderator: Borislav Belev

Borislav Belev
Ključne studije koje su mijenjale kliničku praksu i smjernice mKRK
Key Studies That Shaped Clinical Practice and Guidelines in mCRC

Juraj Prejac
CR Sequence studija i njezin značaj za liječenje mKRK
The CR Sequence Study and Its Impact on the Treatment of mCRC

Nikša Librenjak
Iskustva iz kliničke prakse
Translating Evidence into Practice

Appendiceal Cancer Care – What clinicians need  to know?

Case report

Panel discussion

New therapies on the horizon for GI and hepatobiliary tumors

Case report

Panel discussion

Case report

Panel discussion

Coffee break and poster viewing

Jedna pacijentica, mnogo izazova: multidisciplinarni pristup platina-rezistentnom raku jajnika uz primjenu lijeka ELAHERE
One Patient, Many Challenges: A Multidisciplinary Approach to Platinum-Resistant Ovarian Cancer with ELAHERE

Panel rasprava / Panel Discussion
Panelisti / Panelists: Branka Petrić Miše, Tihana Boraska Jelavić, Kristina Katić, Marija Milković Periša, Igor Petriček

SATELITSKI SIMPOZIJ AstraZeneca
SATELLITE SYMPOSIUM AstraZeneca
Od FLOT-a do D-FLOT-a: što MATTERHORN mijenja
u perioperativnom liječenju?
From FLOT to D-FLOT: what does MATTERHORN change
in perioperative treatment?
Moderator: Juraj Prejac
Panelisti / Panelists: Marin Golčić, Andrija Katić,
Nikša Librenjak

Melanoma treatment outcomes in Croatia following the introduction of targeted therapy and immune checkpoint inhibitors

SATELITSKI SIMPOZIJ AstraZeneca
SATELLITE SYMPOSIUM AstraZeneca
Barijere u skrbi bolesnica s rakom dojke u RH
(i pokoje praktično rješenje)
Barriers to breast cancer care in Croatia (and a few practical
solutions)
Moderator: Natalija Dedić Plavetić
Predavači / Lecturers: Anuška Budisavljević, Marija Križić,
Danijel Antonio Grubišić

Stjepko Pleština
Napredak u liječenju uznapredovalog raka želuca: gdje smo danas?
Advances in the Treatment of Advanced Gastric Cancer: Where Are We Today?

Moderator: Stjepko Pleština
Juraj Prejac
Od znanstvenih dokaza do kliničke prakse: hrvatsko iskustvo u liječenju bolesnika s mCRC
From Scientific Evidence to Clinical Practice: The Croatian Experience in the Treatment of Patients with mCRC

Lunch

Sanja Pleština, Dragan Trivanović
Serplulimab: Nova terapijska opcija u liječenju SCLC
Serplulimab: A New Therapeutic Option for the Treatment of SCLC

Juraj Prejac
Dvojna imunoterapija u prvoj liniji liječenja MSI-H/dMMR
metastatskog kolorektalnog karcinoma
Dual Immunotherapy in First-line MSI-H/dMMR Metastatic
Colorectal Cancer

Juraj Prejac, Goran Adžić
BREAKWATER – Novi pristup u prvoj liniji liječenja BRAF V600E mCRC
BREAKWATER: Advancing First-line Treatment in BRAF V600E mCRC

Marko Jakopović, Sanja Pleština
Više od preživljenja: nova perspektiva NSCLC-a
Beyond Survival: Evolving Perspectives in NSCLC Management

Stjepko Pleština, Domina Kekez
Novosti u liječenju bolesnika s metastatskim kolorektalnim karcinomom
Updates in the Treatment of Patients with Metastatic Colorectal Cancer

Coffee break and poster viewing

Oral presentations of selected papers

Why it is not optimal to start antipain therapy with transdermal preparations, opioid conversion, elastomeric pumps and hypodermoclysis

Adjuvant analgesics, drugs at the end of life and education of professionals

„Pain Management in Palliative Care for Patients With Cancer: Advances and Research for Treatment of Specific Cancers“ – book presentation

Discussion and take-home message

Screening for brain metastases: for whom, when, and does it make sense?

When to postpone radiotherapy of brain metastases in favor of "upfront" systemic therapy?

Follow-up of patients with brain metastases: for whom, when, and is it worthwhile?

Locoregionally advanced squamous cell carcinoma of the head and neck – are we ready for a new treatment paradigm?

Recurrent and metastatic head and neck cancer – what comes after immunotherapy?

Panel discussion

What do you need to know before starting treatment for non-small cell lung cancer (what is sufficient for a diagnosis?

The role of targeted therapy in the treatment of early – and advanced-stage lung cancer

Everyday dilemmas and the art of treating lung cancer patients with immunotherapy

Novartis panel discussion: Meet the Expert

Kisqali® (ribociklib): Dokazi, klinička iskustva i očekivanja u liječenju HR+/HER2− raka dojke
Kisqali® (ribociclib): Evidence, Experience and Expectations in HR+/HER2− Breast Cancer

Moderatorica / Moderator: Anuška Budisavljević
Panelisti / Panelists: Dejan Jurić, Ana Tečić Vuger, Martina Bašić Koretić, Iva Skočilić

Coffee break and poster viewing

Kristina Krpina
Perioperativna primjena imunoterapije lijekom OPDIVO u
resektabilnom NSCLC-u: utjecaj na ishode liječenja
Perioperative OPDIVO: Transforming Outcomes in Resectable
NSCLC

Sanja Pleština, Vide Popović
Od dokaza do svakodnevne kliničke prakse – Stručni osvrt na liječenje prve linije uznapredovalog ALK+NSCLC
From Evidence to Everyday Practice – Expert Perspectives on First-Line Treatment in ALK+ Advanced NSCLC

Challenges of potentially operable stage III non-small cell lung cancer

Panel discussion

TAGRISSO: Kontinuum liječenja EGFR-mutiranog
nesitnostaničnog raka pluća
TAGRISSO: Treatment Continuum of EGFR-Mutated
Non-Small Cell Lung Cancer
Predavači / Lecturers: Marko Jakopović, Sanja Pleština,
Vide Popović, Nenad Kunac, Lela Bitar

12:45 – 13:00 Natalija Dedić Plavetić
Odabir optimalnog liječenja ranog HR+, HER2- raka dojke
Choosing the Optimal Treatment for Early HR+, HER2- Breast Cancer

13:00 – 13:15 Anuška Budisavljević
Abemaciklib u HR+, HER2- raku dojke: RWE podaci
Abemaciclib in HR+, HER2- Breast Cancer: Real-World Evidence (RWE) Data

13:15 – 13:30 Ana Tečić Vuger
Adjuvantni CDK4/6 inhibitori i utjecaj na kvalitetu života
Adjuvant CDK4/6 Inhibitors and Quality of Life

Natalija Dedić Plavetić

Konjugati protutijela i lijeka u liječenju raka dojke: širenje terapijskih mogućnosti
ADC in Breast Cancer: Expanding the Treatment Landscape

Mirela Šambić Penc
MIUC: Adjuvantna imunoterapija u visokorizičnom MIUC-u:
nova perspektiva liječenja uz OPDIVO
MIUC: Adjuvant Immunotherapy in High-Risk MIUC:
Changing the Course of Disease with OPDIVO

Lunch

Radionica: „Indikacija za NE”
Kada, kome i kako reći NE bez grižnje savjesti
Workshop: „Indication for NO”
When, to Whom, and How to Say No Without Guilt

Današnje nezadovoljene medicinske potrebe u liječenju SCLC i oblikovanje sljedeće terapijske ere
Addressing Unmet Need in SCLC Today and Shaping the Next Treatment Era

Moderator: Marko Jakopović

15:00 – 15:13 Dražena Srdić
SCLC danas: od imunoterapije prve generacije blokadom PD-L1 do imunoterapije sljedeće generacije aktivacijom T-limfocita tarlatamabom
SCLC Today: From First-Generation PD-L1 Blockade to Next-Generation T-Cell Engagement with Tarlatamab

15:13 – 15:25 Marijo Boban
Od dokaza u drugoj liniji do novih mogućnosti u prvoj liniji: DeLLphi-304 i terapijske strategije liječenja u razvoju za SCLC
From Second-Line Evidence to the First-Line Frontier: DeLLphi-304 and Emerging Treatment Strategies in SCLC

Moderator: Maja Baučić
Predavači / Lecturers: Maja Baučić, Marin Prpić

Nubeqa u liječenju raka prostate – od kliničke prakse do znanstvenih dokaza
Nubeqa in the treatment of prostate cancer – from clinical practice to scientific evidence

Marko Jakopović, Vide Popović, Jasna Radić

Novi korak. Nova mogućnost. Novi pristup liječenju NSCLC-a
A New Step. A New Opportunity. A New Approach to NSCLC Treatment

Marijana Jazvić
Kontrola tumorske progresije RCC-a uz kabozantinib
Control of Tumor Progression in RCC with Cabozantinib

Prostate cancer: More than PSA – precision oncology in prostate cancer

Prostate cancer: Case report of a patient with metastatic castration-refractory prostate cancer

Prostate cancer: Panel discussion

Svijetla budućnost za rak prostate

A bright future for prostate cancer

Urothelial carcinoma: Prevention of permanent damage – timely diagnosis and treatment of neurological side effects of oncological therapy

Urothelial carcinoma: Case report of a patient with non-muscle-invasive bladder cancer

Urothelial carcinoma: Case report of a patient with muscle-invasive bladder cancer

Urothelial carcinoma: Panel discussion

Kliničke dileme u liječenju raka mokraćnog mjehura: možemo li odgoditi/izbjeći cistektomiju?

Clinical dilemmas in the treatment of bladder cancer: can we delay or avoid cystectomy?

Testicular cancer: What isn't in the guidelines?

Tomislav Omrčen, Zrna Antunac Golubić, Dražen Huić
Počinje novo doba liječenja PSMA+ mCRPC-a u Hrvatskoj: vrijeme je za Pluvicto!
A New Era in the Treatment of PSMA+ mCRPC In Croatia: It’s Time for Pluvicto!

Natalija Dedić Plavetić, Otto Metzger, Ana Tečić Vuger
Što donosi budućnost liječenja HER2-pozitivnog metastatskog raka dojke? Obećavajuće nove terapije koje utječu na algoritam liječenja
What’s Next for HER2+ Metastatic Breast Cancer? Promising New Therapies Reshaping the Future Treatment Landscape

Panel discussion 1 – Improving Outcomes in Early Breast Cancer While Minimizing Long-Term Toxicity

Panel discussion 2 – Advanced Breast Cancer — A Moving Target with Many Faces

Access to Innovative Therapeutic Options for Breast Cancer: Challenges and Solutions

Coffee break and poster viewing

Od znanstvenih dokaza do kliničke prakse u HR+/HER2− ranom raku dojke
From Science to Clinical Practice in HR+/HER2- Early Breast Cancer

11:15 – 11:25 Natalija Dedić Plavetić
Put prema dugoročnom smanjenju rizika u ranom raku dojke
The Pursuit of Long-Term Risk Reduction in Early Breast Cancer

11:25 – 11:50 Dejan Jurić
Promjena tijeka ranog raka dojke: znanstveni dokazi u pozadini
Changing the Trajectory of Early Breast Cancer: The Evidence Behind

11:50 – 12:00 Natalija Dedić Plavetić, Dejan Jurić
Rasprava / Q&A part

Ovarian cancer after PARP inhibitors – What can we offer to patients who have exhausted all treatment options?

Endometrial cancer – immunotherapy for all or for selected patients?

Where are we today and where are we headed tomorrow in the treatment of locally advanced cervical cancer

Panel discussion

Lunch